These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats. Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433 [TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice. Lin YC; Adamson RH; Clark JF; Reed RK; Curry FR J Physiol; 2012 Jan; 590(2):309-22. PubMed ID: 22083598 [TBL] [Abstract][Full Text] [Related]
12. Roflumilast Reduces Cerebral Inflammation in a Rat Model of Experimental Subarachnoid Hemorrhage. Wu Q; Qi L; Li H; Mao L; Yang M; Xie R; Yang X; Wang J; Zhang Z; Kong J; Sun B Inflammation; 2017 Aug; 40(4):1245-1253. PubMed ID: 28451841 [TBL] [Abstract][Full Text] [Related]
14. The Effect of Roflumilast on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice. Kim KY; Kim YA; Joo HS; Kim JW In Vivo; 2024; 38(3):1127-1132. PubMed ID: 38688656 [TBL] [Abstract][Full Text] [Related]
15. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs. Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047 [TBL] [Abstract][Full Text] [Related]
16. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD]. Martínez FJ Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811 [No Abstract] [Full Text] [Related]
17. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways. Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122 [TBL] [Abstract][Full Text] [Related]
18. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913 [TBL] [Abstract][Full Text] [Related]
19. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease. Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484 [TBL] [Abstract][Full Text] [Related]
20. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]